LCTX

Lineage Cell Therapeutics Inc. (LCTX) | Rumor.io

Lineage Cell Therapeutics

LCTX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,225

Bullish sentiment (50-day avg)84%

Price to earnings ratio-3.41

Market capitalization245.3M

Earnings per share-0.19

Dividend yield (TTM)—

Revenue (annual)14.6M

Net income (annual)-63.4M

Social

What share of all stock conversation is about LCTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.01% +0	0% +0	0% 0

Sep 28

Lineage Cell Therapeutics, Inc. ($LCTX) OpRegen remains strategically positioned in Roche's ophthalmology pipeline, with a focus on surgical and delivery progress, and positioning 36-month data as evidence of cell therapy's potential.
The Phase 2a GAlette study's primary efficacy and surgical readouts are expected to be released in late 2026 or early 2027, which would largely derisk the OpRegen platform.
OpRegen (RG6501) was featured as part of Roche's pipeline updates at the 2026 Pharma Day, with a focus on surgical and delivery progress, and positioning 36-month data to validate the therapy's long-term results.

Generated by AI

Sentiment

Of the messages about LCTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +42.86	68.42% -23.89	78.4% -10.28	91.53% -3.79
Bearish	0% -42.86	31.58% +23.89	21.6% +10.28	8.47% +3.79

Bullish· Nov 24

$LCTX's manufacturing and platform capabilities have been proven, which could lead to significant value in the future.
The company's progress and program success are accelerating, with sufficient capital already raised and warrants that can be exercised to bring in more funding.
The triggered payment from Roche is a vote of confidence in $LCTX's technologies, which are progressing and have the potential to be worth billions if proven successful.

Bearish· May 4

The asset's OpRegen treatment may be experiencing a "sell the news" situation, where the market's reaction to new data could lead to a decline in value.
The treatment's durability and potential for structural recovery are not yet fully understood, which may be a concern for investors.
The asset's recent performance and technical indicators suggest a sideways or downward trajectory, with the RSI at 36.04 and the MACD at -0.0283.

Generated by AI

Topics

Of the messages about LCTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	98.13%	87.04%
Technical Analysis	0%	0%	0.63%	6.96%
Analysts	0%	0%	1.25%	3.07%
Earnings	0%	0%	0%	1.33%
Controversies	0%	0%	0%	0.96%
Macro	0%	0%	0%	0.63%

Aug 26

Lineage Cell Therapeutics ($LCTX) has partnered with William Demant Invest to develop ReSonance (ANP1), a cell therapy for treating hearing loss, with up to $12 million in funding over 3 years.
The collaboration will advance ReSonance through preclinical development activities, with joint management and control by Lineage and scientists from Eriksholm Research Centre.
This partnership strengthens Lineage's position in regenerative medicine for hearing loss and provides financial and scientific support at a crucial point in the development process.

Generated by AI

Community

Of the messages about LCTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	72.73%	98.21%	98.76%	92.43%
Newcomers	27.27%	1.79%	1.24%	7.57%

Regulars· Sep 28

Roche's ophthalmology pipeline is thin, and OpRegen's success will be crucial for the company's future.
OpRegen is well-positioned within Roche's ophthalmology division, with clinical durability and manufacturing/process-development work underway.
Lineage Cell Therapeutics' OpRegen is featured as part of Roche's pipeline updates at the Roche Pharma Day 2026 in London, with promising long-term Phase 1/2a results and subretinal delivery method optimization.

Newcomers· Feb 18

Newcomers are interested in $LCTX and its potential for a big move.
There is speculation about whether $LCTX is a good long-term investment opportunity.
The asset's price movement is being discussed as a possible indicator of future performance.

Generated by AI

News

Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform

CARLSBAD, Calif., September 08, 2026--AlloSCOPE 5D Patent Release

22d agoYahoo Finance

Lineage Cell Therapeutics: Balancing An Out-Licensed Pipeline Against Clinical Risk

Lineage Cell Therapeutics is rated Hold due to its reliance on out-licensing and a risk-adjusted fair value below the current share price. Click for more.

28d agoSeeking Alpha

Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript

Detailed price information for Lineage Cell Therapeutics Inc (LCTX-A) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Lineage Cell Therapeutics Q2 Earnings Call Highlights

1mo agoYahoo Finance

Lineage Cell Therapeutics, Inc. Q2 2026 Earnings Call Summary

1mo agoYahoo Finance

Lineage Cell Therapeutics Inc (LCTX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended, ...

Lineage Cell Therapeutics Inc (LCTX) reports net income of $1.5 million, extends cash runway into Q3 2028, and advances key pipeline programs despite revenue decline.

1mo agoYahoo Finance

Also Discussed

Investors talking about LCTX also mention

#	Name	Attention
1	MediWound Ltd.MDWD	0%0
2	APLS - Apellis Pharmaceuticals, Inc.	——
3	Century Therapeutics IncIPSC	0%0
4	STAAR Surgical CompanySTAA	0%new
5	Geron CorporationGERN	0%0
6	Kamada Ltd.KMDA	0%0
7	PSTX - Poseida Therapeutics, Inc.	——
8	Serina Therapeutics Inc.SER	0%0
9	DocGo Inc.DCGO	0%0
10	Sana Biotechnology Inc.SANA	0%0

Lineage Cell Therapeutics Inc.

Healthcare
Biotechnology

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel allogeneic, or off‑the‑shelf, cell therapies for serious neurological and ophthalmic conditions. The company leverages a proprietary cell-based technology platform and in-house development and manufacturing capabilities to design, produce, and test specialized human cells with anatomical and physiological functions similar to those found naturally in the body. These cells are generated from well-characterized pluripotent cell lines using directed differentiation processes, then transplanted to replace or support cells lost or damaged by degenerative disease, aging, or traumatic injury. Lineage Cell Therapeutics’ pipeline includes programs targeting dry age-related macular degeneration through retinal pigment epithelium cell replacement, spinal cord injury via oligodendrocyte progenitor cell therapy, oncology applications using dendritic cell vaccines, and additional preclinical candidates in hearing loss and vision restoration. Headquartered in Carlsbad, California, and founded in 1990, the company operates within the biopharmaceutical and medical research ecosystem, collaborating with larger industry partners to advance its cell therapy candidates toward broader clinical use.

Website

Location

2173 Salk Avenue

Carlsbad, CA, 92008

United States

Social

What share of all stock conversation is about LCTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.01% +0	0% +0	0% 0

Sep 28

Lineage Cell Therapeutics, Inc. ($LCTX) OpRegen remains strategically positioned in Roche's ophthalmology pipeline, with a focus on surgical and delivery progress, and positioning 36-month data as evidence of cell therapy's potential.
The Phase 2a GAlette study's primary efficacy and surgical readouts are expected to be released in late 2026 or early 2027, which would largely derisk the OpRegen platform.
OpRegen (RG6501) was featured as part of Roche's pipeline updates at the 2026 Pharma Day, with a focus on surgical and delivery progress, and positioning 36-month data to validate the therapy's long-term results.

Generated by AI

Sentiment

Of the messages about LCTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +42.86	68.42% -23.89	78.4% -10.28	91.53% -3.79
Bearish	0% -42.86	31.58% +23.89	21.6% +10.28	8.47% +3.79

Bullish· Nov 24

$LCTX's manufacturing and platform capabilities have been proven, which could lead to significant value in the future.
The company's progress and program success are accelerating, with sufficient capital already raised and warrants that can be exercised to bring in more funding.
The triggered payment from Roche is a vote of confidence in $LCTX's technologies, which are progressing and have the potential to be worth billions if proven successful.

Bearish· May 4

The asset's OpRegen treatment may be experiencing a "sell the news" situation, where the market's reaction to new data could lead to a decline in value.
The treatment's durability and potential for structural recovery are not yet fully understood, which may be a concern for investors.
The asset's recent performance and technical indicators suggest a sideways or downward trajectory, with the RSI at 36.04 and the MACD at -0.0283.

Generated by AI

Topics

Of the messages about LCTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	98.13%	87.04%
Technical Analysis	0%	0%	0.63%	6.96%
Analysts	0%	0%	1.25%	3.07%
Earnings	0%	0%	0%	1.33%
Controversies	0%	0%	0%	0.96%
Macro	0%	0%	0%	0.63%

Aug 26

Lineage Cell Therapeutics ($LCTX) has partnered with William Demant Invest to develop ReSonance (ANP1), a cell therapy for treating hearing loss, with up to $12 million in funding over 3 years.
The collaboration will advance ReSonance through preclinical development activities, with joint management and control by Lineage and scientists from Eriksholm Research Centre.
This partnership strengthens Lineage's position in regenerative medicine for hearing loss and provides financial and scientific support at a crucial point in the development process.

Generated by AI

Community

Of the messages about LCTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	72.73%	98.21%	98.76%	92.43%
Newcomers	27.27%	1.79%	1.24%	7.57%

Regulars· Sep 28

Roche's ophthalmology pipeline is thin, and OpRegen's success will be crucial for the company's future.
OpRegen is well-positioned within Roche's ophthalmology division, with clinical durability and manufacturing/process-development work underway.
Lineage Cell Therapeutics' OpRegen is featured as part of Roche's pipeline updates at the Roche Pharma Day 2026 in London, with promising long-term Phase 1/2a results and subretinal delivery method optimization.

Newcomers· Feb 18

Newcomers are interested in $LCTX and its potential for a big move.
There is speculation about whether $LCTX is a good long-term investment opportunity.
The asset's price movement is being discussed as a possible indicator of future performance.

Generated by AI

Lineage Cell Therapeutics

Social

Sep 28

Bullish· Nov 24

Bearish· May 4

Aug 26

Regulars· Sep 28

Newcomers· Feb 18

Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform

Lineage Cell Therapeutics: Balancing An Out-Licensed Pipeline Against Clinical Risk

Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript

Lineage Cell Therapeutics Q2 Earnings Call Highlights

Lineage Cell Therapeutics, Inc. Q2 2026 Earnings Call Summary

Lineage Cell Therapeutics Inc (LCTX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended, ...

Also Discussed

Lineage Cell Therapeutics Inc.

Company Information

Location

Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform

Lineage Cell Therapeutics: Balancing An Out-Licensed Pipeline Against Clinical Risk

Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript

Lineage Cell Therapeutics Q2 Earnings Call Highlights

Lineage Cell Therapeutics, Inc. Q2 2026 Earnings Call Summary

Lineage Cell Therapeutics Inc (LCTX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended, ...

Also Discussed

Social

Sep 28

Bullish· Nov 24

Bearish· May 4

Aug 26

Regulars· Sep 28

Newcomers· Feb 18